Insulin Resistance And End Stage Renal Disease: The Role Of Retinol Binding Protein 4

NCT ID: NCT00910130

Last Updated: 2009-05-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether Retinol binding protein 4 has a role in insulin resistance development in patients suffering from end stage renal disease on hemodialysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance Diabetes End Stage Renal Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Retinol Binding Protein 4 Insulin Resistance Diabetes End Stage Renal Disease Dialysis Nutrition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

End Stage Renal Disease

Patients suffering from End Stage Renal Disease on Hemodialysis, without Diabetes

No interventions assigned to this group

Control

Healthy people, with normal Renal Function and without Diabetes, matched with "ESRD group" for age, gender, BMI

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hemodialysis for "End Stage Renal Disease group"
* Normal Renal Function for "Control group"

Exclusion Criteria

* Diabetes
* Malnutrition
* Malignancy
* Acute Infection
* Chronic Active Infection
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Unit Of Nephrology, Dialysis And Transplantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Giovanni Piotti, MD

Role: PRINCIPAL_INVESTIGATOR

Unit Of Nephrology, Dialysis And Transpantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy

Teresa Rampino, MD

Role: STUDY_DIRECTOR

Unit Of Nephrology, Dialysis And Transpantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy

Antonio Dal Canton, MD

Role: STUDY_CHAIR

Unit Of Nephrology, Dialysis And Transpantation, IRCCS Fondazione Policlinico San Matteo, Pavia Italy

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Giovanni Piotti

Pavia, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Giovanni Piotti, MD

Role: CONTACT

Phone: +390382502590

Email: [email protected]

Teresa Rampino, MD

Role: CONTACT

Phone: +390382503896

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Giovanni Piotti, MD

Role: primary

Teresa Rampino, MD

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005 Jul 21;436(7049):356-62. doi: 10.1038/nature03711.

Reference Type RESULT
PMID: 16034410 (View on PubMed)

Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med. 2006 Jun 15;354(24):2552-63. doi: 10.1056/NEJMoa054862.

Reference Type RESULT
PMID: 16775236 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RBP4

Identifier Type: -

Identifier Source: org_study_id